… When REGEN-COV was issued emergency use authorization in the … antibodies in
pregnant patients, despite their exclusion from efficacy trials.We hypothesized that REGEN-COV …

… In conclusion, REGEN‐COV antibody cocktail‐treated high‐risk SARS‐CoV‐2 patients
infected with the delta variant showed faster resolution of symptoms along with reduced viral …

Background: REGEN-COV has been approved as a treatment for high-risk patients infected
with SARS-CoV-2 within 5 days of their diagnosis. We aim to determine the real-world …

… These results point to a promising therapeutic approach of co-administering the antibodies
1:1 (REGEN-COV ® antibody combination) to reduce both the viral load of SARS-CoV-2 and …

… Thirteen months prior to writing he received two of five cycles of G-benda, a combination of
… Anti-SARS-CoV-2 vaccine was administered in the window where REGEN-COV antibody …

… As CAS+IMD is a potent antiviral monoclonal antibody combination shown to rapidly reduce
SARS-CoV-2 viral load and modulate a patient’s disease course across various populations …

… In this retrospective analysis of immunodeficient patients granted REGEN-COV under
emergency compassionate use, REGEN-COV treatment was associated with rapid viral clearance …

… This study demonstrates that a combination of non-competing antibodies, REGEN-COV,
not only provides full coverage against current variants of concern/interest but also protects …

… combination are used as high, mid and low quality controls. … effective therapies such as
REGEN-COV will remain [Citation… new anti-SARS-CoV-2 spike antibodies, we have successfully …

… REGEN-COV is a combination of 2 monoclonal antibodies (… We aimed to evaluate the
efficacy and safety of REGEN-COV … plus a single dose of REGEN-COV 8g (casirivimab 4g and …